Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Kyowa Kirin

Tracked across 9 events · 141 articles · First seen Apr 21, 2022 · Last active Sep 21, 2026

Sentiment
24
Attention
6
Events
9
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 75
Tech
Impact: Kyowa Kirin announced positive results from its PROSPER study for mogamulizumab, which is expected to positively impact its stock price and reputation.
Jun 29, 2026 · 7 articles
4 60
Tech
Impact: Kyowa Kirin is presenting new data on its drug Mogamulizumab, which could enhance its market position and revenue. The company is the primary entity driving this event.
Jun 10, 2026 · 10 articles
4 70
Tech
Impact: Kyowa Kirin funded the research and developed mogamulizumab, a drug that showed improved survival outcomes in patients with rare blood cancers, positively impacting the company's reputation and potential market position for its product POTELIGEO.
Jun 30, 2026 · 6 articles
2 30
Business
Impact: Kyowa Kirin is the client adopting Benchling with Cognizant's support, aiming to accelerate R&D and reduce costs. This partnership is expected to improve its drug discovery efficiency and competitive position.
Aug 17, 2026 · 6 articles
6 40
Domestic
On August 31, 2026, President Donald Trump announced voluntary drug pricing agreements with nine pharmaceutical companies: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These companies agreed…
Impact: Kyowa Kirin agreed to MFN pricing and plans to increase U.S. manufacturing, aiming to supply over 95% of its U.S.-manufactured drugs to American patients within two years.
Aug 18, 2026 · 37 articles
4 -30
Business
Impact: Kyowa Kirin was down almost 3% on one day, reflecting losses.
Jul 24, 2026 · 37 articles
4 -30
Business
The Japanese stock market experienced a significant rally over several trading sessions in August 2026, with the Nikkei 225 index surging to record levels above 68,000. The rally was driven by strong gains in technology…
Impact: Kyowa Kirin declined almost 4%, underperforming the market.
Apr 21, 2022 · 26 articles
2 0
Business
Grunenthal, a privately held German pharmaceutical company focused on pain management, announced an agreement with Bayer to acquire the cancer treatment Stivarga (regorafenib) for up to 375 million euros. Stivarga is an oral multikinase inhibitor…
Impact: Kyowa Kirin is referenced as the former joint venture partner of Grunenthal Meds, whose full ownership Grunenthal acquired earlier in 2026, illustrating Grunenthal's ongoing M&A strategy.
Sep 21, 2026 · 6 articles
2 0
Business
Impact: Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan, a product related to Ardelyx's pipeline.
Apr 01, 2026 · 6 articles
United States ↔ Kyowa Kirin
United States ↔ Kyowa Kirin
ERGEN INTELLIGENCE
Track Kyowa Kirin live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.